Evidence map›Paper›PMID 16936143›Full record

Trial reportDiabetes care2006

Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program.

Elizabeth A Walker, Mark Molitch, M Kaye Kramer, Steven Kahn, Yong Ma, Sharon Edelstein, Kellie Smith, Mariana Kiefer Johnson, Abbas Kitabchi, Jill Crandall

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Interventions for enhancing medication adherence.The Cochrane database of systematic reviews · 2014
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
    Trial
  17. Review
  18. Article
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Elizabeth A WalkerDiabetes Prevention Program, Coordinating Center, George Washington University Biostatistics Center, 6110 Executive Blvd. #750, Rockville, MD 20852, USA. dppmail@biostat.bsc.gwu.edu
Mark Molitch
M Kaye Kramer
Steven Kahn
Yong Ma
Sharon Edelstein
Kellie Smith
Mariana Kiefer Johnson
Abbas Kitabchi
Jill Crandall
Albert Einstein College of Medicine · USGeorge Washington University · USNorthwestern University · USThomas Jefferson University · USUniversity of Pittsburgh · USUniversity of Tennessee Health Science Center · USUniversity of Washington · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
NIDDK NIH HHS U01 DK048489
6 · The paper itself

Abstract

objectiveTo evaluate barriers to and strategies for medication adherence and predictors of adherence and the primary outcome in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND

methodsWithin a randomized, controlled primary prevention study for type 2 diabetes, we collected data on study medication adherence, its predictors, and health outcomes in 27 clinical centers across mainland U.S. and Hawaii. Medication arm participants included 2,155 adults with impaired glucose tolerance randomly assigned to either metformin or matched placebo treatment arms. Structured interviews were used to promote medication adherence and to collect data regarding adherence. Adherence was measured by pill count. The primary DPP outcome of type 2 diabetes was assessed by fasting plasma glucose and oral glucose tolerance test.

resultsOlder age-groups were more adherent than the youngest group (P = 0.01) in the metformin group. The most frequently reported barrier to adherence was "forgetting" (22%). Women reported more adverse effects of metformin (15 vs. 10%, P = 0.002) in the metformin group. Odds of nonadherence increased as participants reported more than one barrier (odds ratio 19.1, P < 0.001). Odds of adherence increased as participants reported multiple strategies to take medication (2.69, P < 0.0001). There was a 38.2% risk reduction for developing diabetes for those adherent to metformin compared with those adherent to placebo (P < 0.0003).

conclusionsDPP medication adherence results are unique in primary prevention for a chronic disease in a large multiethnic sample. Our finding that adherence was associated with risk reduction for diabetes supports the development of brief interventions in clinical settings where medication adherence is a challenge.

Indexed as

AdultAgedAged, 80 and overBlood GlucoseDiabetes Mellitus, Type 2FemaleGlucose Tolerance TestHumansHypoglycemic AgentsLogistic ModelsMaleMetforminMiddle AgedOdds RatioPatient CompliancePrognosisBlood GlucoseHypoglycemic AgentsMetformin

Identifiers

PMID16936143
PMCPMC1762037
OpenAlexW2159611971

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.